Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.985
+0.085 (4.47%)
Jun 10, 2026, 10:13 AM EDT - Market open
Fate Therapeutics Revenue
Fate Therapeutics had revenue of $1.30M in the quarter ending March 31, 2026, a decrease of -20.26%. This brings the company's revenue in the last twelve months to $6.32M, down -52.64% year-over-year. In the year 2025, Fate Therapeutics had annual revenue of $6.65M, down -51.24%.
Revenue (ttm)
$6.32M
Revenue Growth
-52.64%
P/S Ratio
34.51
Revenue / Employee
$39,230
Employees
161
Market Cap
231.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.65M | -6.99M | -51.24% |
| Dec 31, 2024 | 13.63M | -49.90M | -78.55% |
| Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
| Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
| Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
| Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
| Dec 31, 2019 | 10.68M | 5.94M | 125.32% |
| Dec 31, 2018 | 4.74M | 634.00K | 15.44% |
| Dec 31, 2017 | 4.11M | -296.00K | -6.72% |
| Dec 31, 2016 | 4.40M | 1.97M | 81.08% |
| Dec 31, 2015 | 2.43M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 971.00K | -1.70M | -63.63% |
| Dec 31, 2012 | 2.67M | 1.50M | 128.21% |
| Dec 31, 2011 | 1.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| Cellectis | 75.11M |
| Q32 Bio | 53.74M |
| Coherus Oncology | 46.88M |
| Orchestra BioMed Holdings | 32.72M |
| Entrada Therapeutics | 5.74M |
| AC Immune | 4.62M |
| SAB Biotherapeutics | 114.70K |
FATE News
- 6 days ago - Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - GlobeNewsWire
- 6 days ago - Fate Therapeutics management to meet with Piper Sandler - TheFly
- 7 days ago - Fate Therapeutics Slides: Corporate presentation - Filings
- 7 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting - GlobeNewsWire
- 19 days ago - Fate Therapeutics price target raised to $2.20 from $2 at BofA - TheFly
- 20 days ago - Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - GlobeNewsWire
- 21 days ago - Fate Therapeutics assumed with a Buy at Jefferies - TheFly